39th week of 2013 patent applcation highlights part 58 |
Patent application number | Title | Published |
20130252983 | ACTIVATING PHOSPHORYLATION SITE ON GLUTAMINASE C - A method of reducing the production of glutamate from glutamine by glutaminase C in a cell or tissue. The method involves inhibiting activating phosphorylation of glutaminase C under conditions effective to reduce production of glutamate from glutamine. Methods for treating or preventing a condition mediated by the activating phosphorylation of glutaminase C, detecting a condition mediated by the activating phosphorylation of glutaminase C, and screening for compounds capable of treating or preventing cancer are also disclosed. | 2013-09-26 |
20130252984 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 2013-09-26 |
20130252985 | Flavoring Systems for Pharmaceutical Compositions and Methods of Making Such Compositions - A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof. Pharmaceutical compositions of the invention include a flavoring system of the invention, a solvent system, and at least one pharmaceutically active agent, such as lopinavir or derivatives thereof, ritonavir or derivatives thereof, or mixtures thereof. Methods for making such liquid pharmaceutical compositions are also disclosed. | 2013-09-26 |
20130252986 | COMPOUNDS - The present invention relates to novel compounds that inhibit Lp-PLA | 2013-09-26 |
20130252987 | METHOD OF REGULATING PLASMA LIPOPROTEINS - A method of modulating the level of lipoproteins in human cells comprising the step of inhibiting resistin in the cells or cellular environment. The method is useful to treat cardiovascular disease. | 2013-09-26 |
20130252988 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS - Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of compound which is which is N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or a hydrate thereof. | 2013-09-26 |
20130252989 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 2013-09-26 |
20130252990 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 2013-09-26 |
20130252991 | Combination - The present invention relates to methods of treating neuroblastoma, osteosarcoma, and rhabdomyosarcoma in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a neuroblastoma treatment method that includes administering 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione, or a pharmaceutically acceptable salt thereof, to a human in need thereof. | 2013-09-26 |
20130252992 | CYCLIC N,N'-DIARYLTHIOUREA - ANDROGEN RECEPTOR ANTAGONIST, ANTI BREAST CANCER COMPOSITION AND USE THEREOF - The present invention relates to novel cyclic N,N′-diarylurea-androgen receptor antagonist, anti-cancer agent, pharmaceutical composition, medicament, and method for treatment of breast cancer disease. | 2013-09-26 |
20130252993 | TRICYCLIC COMPOUND AND USE THEREOF - The present invention relates to the compound represented by formula (I): | 2013-09-26 |
20130252994 | Benzoic Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydrocodone, Prodrugs, Methods of Making and Use Thereof - The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology. | 2013-09-26 |
20130252995 | METHODS FOR REDUCING BINGE OR COMPULSIVE EATING - Compositions, uses, kits and methods for reducing binge or compulsive eating are described herein. Methods may include administering an effective combination of a dosage of a bupropion or a pharmaceutically acceptable salt thereof, and a dosage of naltrexone or a pharmaceutically acceptable salt thereof. Methods may include identifying a patient who is overweight or obese and providing an effective combination of bupropion and naltrexone to the patient. Methods may include reducing a number of binge or compulsive eating events. Methods may include reducing severity of binge or compulsive eating events. | 2013-09-26 |
20130252996 | METHODS AND KITS FOR TREATING CLUSTER HEADACHE DISORDERS - The invention features methods and kits employing bromolysergide in therapies for the treatment of cluster headache disorders. | 2013-09-26 |
20130252997 | TREATING UNWANTED OCULAR CONDITION USING AN ASCOMYCIN MACROLACTAM - The present invention provides compositions and uses of an ascomycin macrolactam for the treatment of an unwanted ocular condition occurring in a patient undergoing treatment with a therapeutically active agent for the treatment of cancer. | 2013-09-26 |
20130252998 | CCI-779 FORMULATIONS FOR PARENTERAL ADMINISTRATION - This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent. | 2013-09-26 |
20130252999 | 2-PHENYL-4-QUINOLONES AS ANTICANCER AGENTS - 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Na | 2013-09-26 |
20130253000 | TREATMENT OF SOLID TUMORS WITH RAPAMYCIN DERIVATIVES - The present invention is directed to the use of rapamycin derivatives for use in treating solid tumors, optionally in combination with a chemotherapeutic agent. | 2013-09-26 |
20130253001 | HIGHLY SOLUBLE SALT OF PYRROLOQUINOLINE QUINONE AND METHOD FOR PRODUCING THE SAME - An object of the present invention is to provide a salt of pyrroloquinoline quinone having a high solubility in water and in an organic solvent and a method for producing the same. | 2013-09-26 |
20130253002 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X | 2013-09-26 |
20130253003 | METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY - Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”). | 2013-09-26 |
20130253004 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT FIBROSIS - Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases. | 2013-09-26 |
20130253005 | SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY - Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents. | 2013-09-26 |
20130253006 | 2-SELENOPHENE-4-QUINOLONES AS ANTICANCER AGENTS - 2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Na | 2013-09-26 |
20130253007 | Compounds That Modulate Oxidative Stress - The present invention provides methods of identifying compounds that selectively induce an oxidative stress response in a biological sample. The present invention further provides methods of treating a subject having a disease associated with oxidative stress using compounds that selectively induce an oxidative stress response in the subject. The invention further provides methods of selectively inducing an oxidative stress response in a cell. | 2013-09-26 |
20130253008 | SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARATION AND USE THEREOF - The present invention relates to novel azoles, novel antiviral active components of the general formulas 1A and 1B, pharmaceutical composition, antiviral medicament, method for prophylaxis and treatment of viral diseases, particularly caused by hepatitis C viruses (HCV). In general formulas 1A and 1B | 2013-09-26 |
20130253009 | Compositions for Drug Administration - The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. | 2013-09-26 |
20130253010 | Modulators of Aldhehyde Dehydrogenase Activity and Methods of Use Thereof - The present invention provides compounds that function as modulators of aldehyde dehydrogenase activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. | 2013-09-26 |
20130253011 | INSECTICIDAL COMPOUNDS - The present invention relates to novel triazole derivatives of formula (I) having insecticidal activity, to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests wherein A | 2013-09-26 |
20130253012 | Pyrazole Compounds for Controlling Invertebrate Pests - The present invention relates to a method for controlling invertebrate pests, in particular arthropod pests and nematodes, by using pyrazole compounds of formula I and the salts thereof, the tautomers thereof, the N-oxides thereof and the salts of the tautomers or N-oxides thereof, | 2013-09-26 |
20130253013 | SEROTONIN REUPTAKE INHIBITORS - In one aspect, the invention relates to compounds of formula I: | 2013-09-26 |
20130253014 | Cyclodextrin-Based Microemulsions, and Dermatological Uses Thereof - Described herein are cyclodextrin-stabilized microemulsion systems useful for increasing the solubility, stability, bioavailability, or safety of an active agent for delivery to the skin. The microemulsions may reduce the occurrence of skin irritation or odor upon application. | 2013-09-26 |
20130253015 | Cyclodextrin-Based Microemulsions, and Dermatological Uses Thereof - Described herein are cyclodextrin-stabilized microemulsion systems useful for increasing the solubility, stability, bioavailability, or safety of an active agent for delivery to the skin. The microemulsions may reduce the occurrence of skin irritation or odor upon application. In certain embodiments, the active agent is substantially insoluble in water. | 2013-09-26 |
20130253016 | SYNERGISTIC PARAFFINIC OIL AND BOSCALID FUNGICIDES - Fungicidal compositions comprising a paraffinic oil and 2-chloro-N-(4′-chloro[1,1′-biphenyl]-2-yl)-3-pyridinecarboxamide (boscalid) are provided. The fungicidal compositions may further comprise a pigment. The fungicidal compositions may be provided as oil-in-water (O/W) emulsions which may be used for controlling fungal disease, such as dollar spot or bentgrass dead spot or bermudagrass dead spot, in plants, such as turfgrasses. Methods of applying the fungicidal compositions are also provided. | 2013-09-26 |
20130253017 | Methods of Delivering a Health Care Active by Administering Personal Health Care Articles Comprising a Filmament - A method of delivering a health care active having the steps of administering to a mammal in need of a health benefit or a treatment for a health condition a personal health care article and consuming the article. The article contains one or more filaments that contain a backbone material, a health care active and optionally aesthetic agents, extensional aids, plasticizers, and crosslinking agents. | 2013-09-26 |
20130253018 | Use of Fluopyram for Controlling Nematodes in Crops and for Increasing Yield - The present invention relates generally to the use of pyridylethylbenzamide derivatives for controlling nematodes and to methods particularly useful for controlling nematodes and/or increasing crop yield. | 2013-09-26 |
20130253019 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONDITIONS OR DISEASES OF THE EYE - Described herein is the use of LPA1 antagonists in the treatment or prevention of diseases or conditions of the eye of a mammal. Also described are pharmaceutical compositions that include at least one LPA1 antagonist. | 2013-09-26 |
20130253020 | Treatment of Degenerative Disc Diseases - The present disclosure provides methods treat or prevent a degenerative disc disease in a patient by administering to the patient a therapeutically effective amount of an advanced glycation endproduct (AGE) breaker. Methods for inhibiting the progression of a degenerative disc disease and for reducing the amount of an advanced glycation endproduct (AGE) in an intervertebral disc (IVD) are also provided. | 2013-09-26 |
20130253021 | Methods of Making and Using Thioxothiazolidine and Rhodanine Derivatives as HIV-1 and JSP-1 Inhibitors - The present invention provides methods of making and using 5-(2-(indol-3-yl)-2-oxoethylidene)-3-phenyl-2-thioxothiazolidin-4-one derivatives having HIV-1 or JSP-1 inhibitory activity. | 2013-09-26 |
20130253022 | NOVEL FLUORINATED SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND THEIR METHOD OF USE - Pharmaceutical compositions of the invention include fluorinated sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy, Alzheimer's disease, Parkinson's disease, Huntington's disease, heavy metal toxicity and any neurodegenerative disease involving glutamate toxicity. | 2013-09-26 |
20130253023 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF - Described herein is the LPA1 antagonist 1-{4′-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-bi-phenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions. | 2013-09-26 |
20130253024 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents - The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same. | 2013-09-26 |
20130253025 | FORMULATIONS OF BENDAMUSTINE - Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations. | 2013-09-26 |
20130253026 | METHOD OF TREATING BENDAMUSTINE-RESPONSIVE CONDITIONS IN PATIENTS REQUIRING REDUCED VOLUMES FOR ADMINISTRATION - Methods of treating bendamustine responsive conditions in patients having fluid and/or sodium intake restrictions are disclosed. The methods include identifying patients having such restrictions and in need of bendamustine, and then administering thereto a bendamustine-containing composition in a volume of about 120 ml or less intravenously over a period of about 15 minutes or less. The smaller volumes and reduced sodium load as compared to currently known methods of treatment minimize cardiac and/or renal stress in patients having diseases such as congestive heart failure or renal disease. | 2013-09-26 |
20130253027 | DOSAGES OF ARYLSULFONAMIDE DERIVATIVES - The invention is directed to the therapeutic use of arylsulfonamide derivatives. | 2013-09-26 |
20130253028 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE - The present invention provides a compound, that is a 1-[(2-{[(alkyl or aryl)methyl]oxy}halo or haloalkyl substituted-phenyl)alkyl]-5-hydrocarbyl or substituted hydrocarbyl-1H-pyrazole carboxylic acid or alkylenylcarboxylic acid or a hydrocarbyl or substituted hydrocarbyl sulfonamide of said carboxylic acid or said alkylenylcarboxylic acid, provided however said compound is not a 3-carboxylic acid, a sulfonamide thereof, or a 3-methylenylcarboxylic acid. The compound may be represented by the following formula | 2013-09-26 |
20130253029 | NOVEL BICYCLIC COMPOUNDS - The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR). | 2013-09-26 |
20130253030 | METHODS OF TREATING MIXED DYSLIPIDEMIA - The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate. | 2013-09-26 |
20130253031 | METHODS OF TREATING MIXED DYSLIPIDEMIA - The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate. | 2013-09-26 |
20130253032 | Use of Apoptosis-specific eIF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis - The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for down regulating pro-inflammatory cytokines in a mammal by administering siRNA against eIF-5A1 to the mammal to treat/prevent sepsis and/or hemorrhagic shock. | 2013-09-26 |
20130253033 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 2013-09-26 |
20130253034 | 2'-Arabino-Fluorooligonucleotide N3'-->P5' Phosphoramidates: Their Synthesis and Use - Oligonucleotides with a novel sugar-phosphate backbone containing at least one 2′-arabino-fluoronucleoside and an internucleoside | 2013-09-26 |
20130253035 | CAMKK-BETA AS A TARGET FOR TREATING CANCER - Provided herein are compounds, compositions, including pharmaceutical compositions, having anti-cancer activity. Also provided are methods for diagnosing, detecting, and treating cancer in a subject, as well as a method for evaluating cancer stage in a subject, wherein the methods include determining the amount of a Ca | 2013-09-26 |
20130253036 | TREATMENT OF ALPHA-L-IDURONIDASE (IDUA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IDUA - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Alpha-L-Iduronidase (IDUA), in particular, by targeting natural antisense polynucleotides of Alpha-L-Iduronidase (IDUA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IDUA. | 2013-09-26 |
20130253037 | AURORA A KINASE EFFECTORS - Two proteins (PHLDA1 and LIMK2) have been identified as direct targets of Aurora A kinase activity. PHLDA1 downregulation and Aurora A upregulation are strong predictors of poor prognosis for breast cancer patients. In accordance with one embodiment a method of detecting, prognosing and monitoring the presence/progression of cancer, and more specifically breast or prostate cancer, is provided. In one embodiment the method comprises the step of analyzing a biological sample from a patient to detect and/or quantitate the presence of Aurora A, PHLDA1 or LIMK2 amino acid sequences. In one embodiment a method of treating cancer is provided comprising the administration of therapies that enhance the activity of PHLDA1 and/or decrease the activity of LIMK2. | 2013-09-26 |
20130253038 | Modified Single-Stranded Polynucleotide - It is intended to provide a polynucleotide that is resistant to RNase and has an RNA interference effect, etc. The present invention provides a single-stranded polynucleotide that is derived from a double-stranded polynucleotide comprising a sense strand polynucleotide corresponding to a target gene, and an antisense strand polynucleotide having a nucleotide sequence complementary to the sense strand polynucleotide, and has a structure in which the 5′-end of the antisense strand and the 3′-end of the sense strand are linked via a phenyl group-containing linker to form a phosphodiester structure at each of these ends. | 2013-09-26 |
20130253039 | COLORECTAL CANCER TREATMENTS AND DIAGNOSTIC IMPROVEMENTS - Cancer cells that exhibit low levels of NMNAT are refractory to tiazofurin therapy, and diagnostic methods for assessing NMNAT levels, particularly human NMNAT2, are described, as are compositions and methods for enhancing cytotoxicity towards tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide), a pro-drug metabolized by nicotinamide mononucleotide adenylyltransferase (NMNAT) to TAD (thiazole-4-carboxamide adenine dinucleotide). Examples of such compositions include gene delivery vehicles that provide for enhanced NMNAT expression in transfected cells, as well as targeted drug delivery compositions that include tiazofurin encapsulated in folate-tethered nanoparticles. This approach shows that increasing NMNAT levels, particularly hNMNAT2 levels, enhances tiazofurin-mediated cell killing, which has relevance in the treatment of various disease, including various cancers and infectious diseases. | 2013-09-26 |
20130253040 | METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE - Disclosed herein are methods and compositions for treating or preventing Huntington's Disease. | 2013-09-26 |
20130253041 | Methods of Treating Neurodegenerative Disease - The present disclosure provides a method of increasing the level and/or function of an Eph receptor B2 in a neuronal cell; and methods of treating an amyloid-beta-induced neurodegenerative disease in an individual. The present disclosure further provides methods of identifying an agent that increases the level and/or function of an Eph receptor B2 in a neuronal cell. | 2013-09-26 |
20130253042 | Oligonucleotide Conjugates - Oligonucleotide conjugates, where an oligonucleotide is covalently attached to an aromatic system, are provided. In particular embodiments the oligonucleotide is complementary to the RNA component of human telomerase and is covalently attached to a nucleobase via an optional linker. The conjugates inhibit telomerase enzyme activity. | 2013-09-26 |
20130253043 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF G-CSF - The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity. | 2013-09-26 |
20130253044 | TAXANE ANALOGS FOR THE TREATMENT OF BRAIN CANCER - Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer. | 2013-09-26 |
20130253045 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses - The present invention relates to prodrugs of compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The prodrugs of the compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention of cancer. | 2013-09-26 |
20130253046 | METHODS OF TREATING CANCER COMPRISING TARGETING NQO1 - Disclosed herein are methods for determining whether an individual with cancer is suitable for a treatment with an NQO1 bioactivatable drug, predicting responsiveness of an individual with cancer to a treatment with an NQO1 bioactivatable drug, and treating an individual with cancer with an NQO1 bioactivatable drug composition. | 2013-09-26 |
20130253047 | METHOD AND COMPOSITION FOR PREVENTING AND TREATING AVIAN INFLUENZA IN POULTRY - A method and composition for preventing and treating avian influenza utilizes an effective quantity of polyphenolic(s) and its derivatives in combination with a carrier. The anti-avian influenza ingredient having a composition selected from the group consisting of theaflavin, theaflavin-3,3′-digallate, theaflavin-3-monogallate, theaflavin-3 gallate, theaflavin-3′-gallate, thearubigin, gallic acid, tannic acid, (−)-epigallocatechin gallate (EGCG), (−)epigallocatechin (EGC), (+)-epicatechin (EC), (−)-gallocatechin gallate (GCG), and catechin. | 2013-09-26 |
20130253048 | Pharmaceutical Composition for Promoting Osteogenesis Containing Axial-equatorial Aryl-oriented Furofuran-type Lignan, and Pharmaceutical Preparation, Functional Food Product, and Health Food Product Comprising Composition - Provided is a composition that, even when used in a very small amount, has the effect of improving bone density and promoting bone growth, and has few side effects, and also provided are a pharmaceutical preparation for promoting bone growth, functional food product, and health food product containing the composition as an active ingredient. The composition can be obtained from any plant part selected from the group consisting of the bud, leaf, bark or wood of a plant belonging to the family Magnoliaceae. The composition comprises at least one selected from the group consisting of fargesin and physiologically acceptable salts, hydrates, and glycosides thereof. The pharmaceutical preparation, functional food product, and health food product comprising this composition as an active ingredient sufficiently improve bone density and promote bone growth, even when used in small amounts, and therefore realize preventive and/or therapeutic effects against bone disease etc. such as osteoporosis. | 2013-09-26 |
20130253049 | TREATMENT FOR PULMONARY HYPERTENSION - One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the co-administration of these agents is to eliminate or reduce one or more side effects associated with mono-therapy of either agent, as well as one or more side effects associated with other administration routes such as subcutaneous or intravenous administration. | 2013-09-26 |
20130253050 | LIPID RAFT, CAVEOLIN PROTEIN,, AND CAVEOLAR FUNCTION MODULATION COMPOUNDS AND ASSOCIATED SYNTHETIC AND THERAPEUTIC METHODS - The present invention is directed to the modulation of lipid rafts, caveolin proteins, or caveolar functions and processes by platinum(IV) compounds. Caveolae and/or lipid rafts are associated with cell transcription regulation, membrane and cellular transport, cell membrane receptor function, cellular trafficking, antigen presentation, cell differentiation and activation, cytokine modulation, membrane structure and function, and protein modulation. Caveolae, caveolin proteins and lipid rafts are known therapeutic targets for numerous biological functions. Diseases and disorders currently known to be therapeutically targeted through caveolae and/or lipid rafts include diabetes, cancer, cardiovascular diseases, atherosclerosis, pulmonary fibrosis, multiple sclerosis, viral and prion diseases, neuronal disorders, degenerative muscular dystrophies, and autoimmune disorders. | 2013-09-26 |
20130253051 | CONTROLLED CHEMICAL RELEASE OF HYDROGEN SULFIDE - Agents of formula: where R1 and R2 vary independently and are acyl, sulfonyl, phosphoryl, alkyl, substituted alkyl, halogen, aryl, arylalkyl, substituted aryl, heteroaryl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, heterocycle, or heteroatoms; and R3 is H or a member of a ring structure which includes R2, are provided; as are agents of formula: where R1, R2 and R3 vary independently and: R1=OH, OR′, NHR′, NR′R″ (with R′ R″=alkyl, aryl, heteroaryl, etc); R | 2013-09-26 |
20130253052 | ANTI-CANCER COMPOSITIONS AND METHODS - Anti-cancer compositions and methods are described including one or more isothiocyanates and/or isoselenocyanates. Methods of treating a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a composition including an isothiocyanate and/or isoselenocyanate to a subject having a condition characterized by Akt dysregulation. Administering a therapeutically effective amount of a composition including an isothiocyanate and/or isoselenocyanate to a subject detectably increases apoptosis and/or decreases proliferation of cancer cells, particularly cancer cells characterized by Akt dysregulation. | 2013-09-26 |
20130253053 | Method of Treating Skin with microRNA Modulators - Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ active agents that suppress or down-regulate microRNA expression in dermal fibroblast, resulting in enhanced production of collagen, elastin and/or fibrillin in the skin. Also provided are methods for screening for activity against specific microRNAs and the methods of using active agents identified by the screening protocol in the treatment of skin. | 2013-09-26 |
20130253054 | Pesticidal composition containing lambda cyhalothrin and diafenthiuron. - The present invention relates to a composition comprising an effective amount of lambda cyhalothrin in the range of 0.5% to 12%; an effective amount of diafenthiuron in the range of 15% to 70% wherein the ratio of lambda cyhalothrin to diafenthiuron is in the range of 1:4 to 1:35; and at least one agrochemical excipient. | 2013-09-26 |
20130253055 | POWDEROUS FORMULATIONS OF FAT-SOLUBLE ACTIVE INGREDIENTS - Stable powderous formulations containing a fat-soluble active ingredient, e.g., vitamin A, in a matrix of a native lupin protein composition are disclosed. | 2013-09-26 |
20130253056 | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same - Disclosed herein are for example, liquid aqueous compositions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome, dystonia, and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of levodopa and/or carbidopa or ester and/or salt thereof. | 2013-09-26 |
20130253057 | Personal Care Compositions and Methods - A personal care composition includes a cleansing phase and a benefit phase, the cleansing phase having a surfactant and the benefit phase having a lipid bilayer structurant. Methods to enhance skin hydration are also provided. | 2013-09-26 |
20130253058 | SATIETY-INDUCING COMPOSITION - The present invention relates to the field of weight management. The invention particularly relates to a method for inducing satiety. In one of its embodiments, the present invention provides a method for inducing satiety in a human or an animal comprising administering to said human or animal an effective amount of a composition comprising a lipid of which at least part is in a crystal form in the small intestine. | 2013-09-26 |
20130253059 | MIXED FATTY ACID SOAP/FATTY ACID INSECTICIDAL, CLEANING, AND ANTIMICROBIAL COMPOSITIONS - The present disclosure relates to compositions including a fatty acid soap/fatty acid mixture, and methods of use thereof. The compositions include a C5 to C12 fatty acid or mixtures thereof. The compositions show increased activity, e.g., insecticidal, soil removal, antimicrobial activity, at a controlled pH range of about 7.5 to about 9.0. | 2013-09-26 |
20130253060 | Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS) - Use of sPLA | 2013-09-26 |
20130253061 | METHOD OF DROXIDOPA SYNTHESIS - The present application relates to a novel method of preparing L-threo-dihydroxyphenylserine (droxidopa). Specifically, the application is directed to a method of preparing droxidopa via a deprotection step that is an alternative to deprotection steps that have been previously disclosed. The new deprotection strategy is advantageous in that it avoids the need to use hydrogenolysis or hydrazine. | 2013-09-26 |
20130253062 | COMBINATIONS OF ADAPALENE AND BENZOYL PEROXIDE FOR TREATING ACNE LESIONS - Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO. | 2013-09-26 |
20130253063 | STABLE DOSAGE FORMS OF LEVOMILNACIPRAN - The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described. | 2013-09-26 |
20130253064 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS - The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease. | 2013-09-26 |
20130253065 | Inhalable Epinephrine - The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action. | 2013-09-26 |
20130253066 | Use of an S1P Receptor Agonist - The present invention relates to new uses of S1P receptor modulator or agonist such as fingolimod, for reducing or delaying the progression of cerebral atrophy. | 2013-09-26 |
20130253067 | METHOD OF TREATING BLADDER DISORDERS - The present invention relates to dexmecamylamine and the use of dexmecamylamine, substantially free of exo-R-mecamylamine, in the treatment of bladder disorders, including overactive bladder. | 2013-09-26 |
20130253068 | Cosmetic or Dermatological Preparations Containing Licochalcone A or an Extract of Radix Glycyrrhizae inflatae, Containing Licochalcone A - Disclosed are cosmetic or dermatological preparations for the treatment or alleviation of erythema which comprise an aqueous extract of Radix | 2013-09-26 |
20130253069 | Use of DMSO for Destroying Adipocytes and Eliminating Cellulite and Adiposities - The invention relates to the use of DMSO for destroying adipocytes and eliminating cellulite and adiposities, more particularly to the concentrations used for destroying adipocytes (fat cells) and eliminating cellulite and adiposities, in both males and females, resulting in the destruction of adipocytes, or fat cells, and the elimination of fat cells, which, in turn, are affected by rancidity and contain toxins, that is, rancid, fat-containing cells generate cellulite since said cells sustain cellulitic nodules, which, in turn, are observed externally as the “orange peel” effect, which is more common in women and easily identified according to the degree of cellulite, and thus, by eliminating fat cells, adiposity is naturally reduced, and consequently, there is a decrease in localized body fat. | 2013-09-26 |
20130253070 | COMBINATION OF CAROTENOIDS AND EPI-LUTEIN - The invention describes the preparation and use of carotenoid and epi-lutein compositions to treat various ocular diseases. | 2013-09-26 |
20130253071 | Methods and Compositions for Prevention and Treatment of Inflammatory Disease, Autoimmune Disease and Transplant Rejection - The invention provides compositions and methods for reducing one or more symptoms of an autoimmune disease, inflammatory disease, and/or transplant rejection, by the administration to a subject in need thereof a pharmaceutically effective amount of a purified compound of any one of Formulae A-E. The invention's methods are useful for the prevention, amelioration, and treatment of autoimmune disease, inflammatory disease, and/or transplant rejection. | 2013-09-26 |
20130253072 | SOLID COSMETIC MAKEUP COMPOSITION - The present invention relates to a solid cosmetic makeup and/or care composition in the form of a powder comprising, in a physiologically acceptable medium, at least: a fatty phase containing at least one silicone polyamide and a silicone resin, and—at least one pulverulent phase containing at least perlite. | 2013-09-26 |
20130253073 | PHOTOCATALYST COMPOSITION AND PREPARATION FOR THE SAME - A solid solution photocatalyst composition and its preparation method are provided in the present invention. The solid solution photocatalyst can utilize its solid solution structure to regulate the conduction band position, valence band position, conduction band range and valence band range of the different response properties of the photocatalyst, so that oxidoreductive reaction is performed to remove the foul-smelling substances. | 2013-09-26 |
20130253074 | Implantation Material Comprising Biocompatible Polymer - Disclosed herein is a hyaluronic acid epoxide derivative film comprises a polymer containing a hydroxyl (—OH) terminal group. The film is prepared by allowing an epoxy crosslinker to react with a mixture of hyaluronic acid and a polymer containing a hydroxyl (—OH) terminal group and has improved physical strength, in vivo stability, flexibility, adhesiveness to biological tissue, and biocompatibility. | 2013-09-26 |
20130253075 | DERIVATIVES OF NATIVE LIGNIN - The present invention provides derivatives of native lignin having a certain aliphatic hydroxyl content. Surprisingly, it has been found that consistent and predictable antioxidant activity may be provided by selecting for derivatives of native lignin having a certain aliphatic hydroxyl content. | 2013-09-26 |
20130253076 | FRAGRANCE COMPOSITIONS - A rose-like fragrance composition including methyl epijasmonate, provided that a natural jasmine fragrance containing methyl epijasmonate is excluded. The rose-like fragrance composition can also include 2-isopropyl-4-methyl thiazole. | 2013-09-26 |
20130253077 | EMULSIFIER AND PRODUCTION METHOD THEREFOR, AND PRODUCTION METHOD FOR EMULSION - Provided are an emulsifier derived from sugar polymer capable of successfully emulsifying even unsaturated oil, a production method therefore, and a production method for emulsion using the emulsifier. This emulsifier can be obtained by a production method including an emulsification improving step of improving the emulsification of sugar polymer particles dispersed in water. In this emulsification improving step, the emulsification of sugar polymer particles can be improved by an action of an emulsification aid that is at least water-soluble one kind selected from salts, an amphiphilic agent, saccharides, an organic acid, and an amino acid. Alternatively, the emulsification of sugar polymer particles can be improved by storing the sugar polymer particles dispersed in water at a low temperature of 10° C. or lower. | 2013-09-26 |
20130253078 | IMPROVED HYBRID FISCHER-TROPSCH CATALYSTS AND PROCESSES FOR USE THEREOF - Disclosed are hybrid Fischer-Tropsch catalysts containing cobalt deposited on hybrid supports. The hybrid supports contain an acidic zeolite component and a silica-containing material. It has been found that the use of the hybrid Fischer-Tropsch catalysts in synthesis gas conversion reactions results in high C | 2013-09-26 |
20130253079 | HYBRID FISCHER-TROPSCH CATALYSTS AND PROCESSES FOR USE THEREOF - Disclosed are hybrid Fischer-Tropsch catalysts containing cobalt deposited on hybrid supports. The hybrid supports contain an acidic zeolite component and a silica-containing material. It has been found that the use of the hybrid Fischer-Tropsch catalysts in synthesis gas conversion reactions results in high C | 2013-09-26 |
20130253080 | METHOD FOR PREPARING A SULFONATED POLYARYLENE ETHER SULFONE COPOLYMER FOR FUEL CELLS - The present disclosure relates to a method for preparing sulfonated polyarylene ether sulfone copolymer used in fabricating an electrolyte polymer membrane which is core material, the method comprising: A) mixing monomers, 4,4′-dihydroxydiphenyl; bis(4-chlorophenyl)sulfone or bis(4-fluorophenyl)sulfone; and 3,3′-disulfonated-4,4′-chlorodiphenyl sulfone with K | 2013-09-26 |
20130253081 | Devulcanization of Rubber and Other Elastomers - A process for forming a vulcanized elastomer composition. An alternating electric field is applied to a first composition comprising vulcanized crosslinked elastomer particles while the composition is compressed to thereby devulcanize the crosslinked elastomer particles and form a second composition comprising devulcanized elastomer particles A crosslinking agent is added to the second composition comprising the devulcanized elastomer particles. The second composition having the crosslinking agent is then vulcanized to form the vulcanized elastomer composition. | 2013-09-26 |
20130253082 | MULTIFUNCTIONAL BIOCOMPOSITE ADDITIVE COMPOSITIONS AND METHODS - Biocomposite compositions and compositions, which include dried distillers solubles, and which can be used in making biocomposite compositions are described. Methods for preparing the compositions are also described. | 2013-09-26 |